Trial Profile
Second Compassionate Use Program of ParvOryx in Combination Bevacicumab and Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Patients with Recurrent Glioblastoma without Prior Surgery
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 29 Sep 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; H 1PV (Primary) ; H 1PV (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 09 Sep 2017 Results (n=8) assessing the effect of H-1PV in combination with bevacicumab and nivolumab or pembrolizumab, presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
- 01 Jun 2017 New trial record
- 23 May 2017 Preliminary results published in an Oryx GmbH & Co Media Release